363 related articles for article (PubMed ID: 26515417)
1. Platelet P2Y12 Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model.
Thomas MR; Outteridge SN; Ajjan RA; Phoenix F; Sangha GK; Faulkner RE; Ecob R; Judge HM; Khan H; West LE; Dockrell DH; Sabroe I; Storey RF
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2562-70. PubMed ID: 26515417
[TBL] [Abstract][Full Text] [Related]
2. Effect of P2Y12 inhibitors on inflammation and immunity.
Thomas MR; Storey RF
Thromb Haemost; 2015 Aug; 114(3):490-7. PubMed ID: 26156883
[TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
4. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Kiers D; van der Heijden WA; van Ede L; Gerretsen J; de Mast Q; van der Ven AJ; El Messaoudi S; Rongen GA; Gomes M; Kox M; Pickkers P; Riksen NP
Thromb Haemost; 2017 Aug; 117(9):1798-1807. PubMed ID: 28692111
[TBL] [Abstract][Full Text] [Related]
5. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
Traby L; Kollars M; Kaider A; Eichinger S; Wolzt M; Kyrle PA
J Thromb Haemost; 2016 Feb; 14(2):273-81. PubMed ID: 26663880
[TBL] [Abstract][Full Text] [Related]
6. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
7. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
8. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
Schrottmaier WC; Kral JB; Badrnya S; Assinger A
Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
[TBL] [Abstract][Full Text] [Related]
9. Role of P2Y
Zhang Y; Zhang S; Ding Z
Adv Exp Med Biol; 2017; 906():307-324. PubMed ID: 27628007
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression.
Reiner MF; Akhmedov A; Stivala S; Keller S; Gaul DS; Bonetti NR; Savarese G; Glanzmann M; Zhu C; Ruf W; Yang Z; Matter CM; Lüscher TF; Camici GG; Beer JH
Cardiovasc Res; 2017 Jan; 113(1):61-69. PubMed ID: 28028070
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Abergel E; Nikolsky E
Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
[TBL] [Abstract][Full Text] [Related]
12. Development and clinical use of prasugrel and ticagrelor.
Ahmad S; Storey RF
Curr Pharm Des; 2012; 18(33):5240-60. PubMed ID: 22724412
[TBL] [Abstract][Full Text] [Related]
13. Type 2 Diabetes and ADP Receptor Blocker Therapy.
Samoš M; Fedor M; Kovář F; Mokáň M; Bolek T; Galajda P; Kubisz P; Mokáň M
J Diabetes Res; 2016; 2016():6760710. PubMed ID: 26824047
[TBL] [Abstract][Full Text] [Related]
14. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
16. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
17. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
18. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention.
Brice AE; Hernandez GA; Sanchez M; Haynick M; Mendoza CE
Platelets; 2017 May; 28(3):305-309. PubMed ID: 27778525
[TBL] [Abstract][Full Text] [Related]
19. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
20. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
